Clinical and laboratory characteristics of patients eligible for the AIDA protocol
| Characteristic . | Value . |
|---|---|
| No. of patients | 828 |
| Sex, male/female | 438/390 |
| Median age, y (range), no. (%) | 37.2 (1.4-74.7) |
| Patients ≤ 20 | 146 (17.65) |
| Patients > 20 and ≤ 60 | 606 (73.28) |
| Patients > 60 | 75 (9.07) |
| Median WBC count (range), /μL | 2900 (300-570 000) |
| Median platelet count (range), /μL | 24 000 (1000-480 000) |
| Patients with hemorrhagic symptoms at diagnosis, no. (%) | 521 (63.9) |
| Risk category according to Sanz et al,36 no. (%) | |
| High risk | 231 (28.17) |
| Intermediate risk | 432 (52.68) |
| Low risk | 157 (19.15) |
| Not evaluable | 8 |
| Characteristic . | Value . |
|---|---|
| No. of patients | 828 |
| Sex, male/female | 438/390 |
| Median age, y (range), no. (%) | 37.2 (1.4-74.7) |
| Patients ≤ 20 | 146 (17.65) |
| Patients > 20 and ≤ 60 | 606 (73.28) |
| Patients > 60 | 75 (9.07) |
| Median WBC count (range), /μL | 2900 (300-570 000) |
| Median platelet count (range), /μL | 24 000 (1000-480 000) |
| Patients with hemorrhagic symptoms at diagnosis, no. (%) | 521 (63.9) |
| Risk category according to Sanz et al,36 no. (%) | |
| High risk | 231 (28.17) |
| Intermediate risk | 432 (52.68) |
| Low risk | 157 (19.15) |
| Not evaluable | 8 |